CD123-positive AML trial using IL3 CAR-T cells
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML confirmed to be CD123-positive (found on lab testing of your leukemia cells).
- Your AML is relapsed or refractory (it did not respond, came back, or did not stay in remission).
- Bone marrow shows enough leukemia cells: either >5% on microscope exam and/or >0.01% on flow cytometry.
- Your organ function is strong enough for treatment (bilirubin, liver enzymes, and kidney blood tests are within limits).
- Heart and breathing requirements are met (left heart pumping strength is at least 50%, and oxygen levels in room air are at least 92%; no serious lung infection).
- You have no key “not eligible” problems (no brain bleeding/serious brain issues, no major heart rhythm problems, not pregnant/breastfeeding, no significant infections like hepatitis B/C or HIV, and you have not had CAR-T or other gene-modified T-cell therapies before).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
This trial tests a new treatment made from your own immune cells (CAR-T cells) that are designed to find and kill leukemia cells that have the FLT3 protein. It is for people with acute myeloid leukemia (AML) that has not responded to standard therapy or has returned after treatment.
This Phase 1 trial tests an allogeneic immune-cell therapy for adults with CD123-positive acute myeloid leukemia (AML) that has not responded well to standard treatments. It aims to see whether this treatment can control leukemia after medicines and possibly transplant options are no longer suitable.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.